Schonfeld Strategic Advisors LLC Cerevel Therapeutics Holdings, Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $14.6 Billion
- Q2 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 42,575 shares of CERE stock, worth $0. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,575
Previous 1,670
2449.4%
Holding current value
$0
Previous $70,000
2385.71%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CERE
# of Institutions
254Shares Held
154MCall Options Held
2.19MPut Options Held
3.92M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...